Three Ewha Research Teams Selected for the 2023 Korea Health Technology R&D Project
- 작성처
- Date2023.07.26
- 12544
Three Ewha Research Teams Selected for the 2023 Korea Health Technology R&D Project
Ewha’s researchers have marked the outstanding achievement of being consecutively selected for major projects of the 2023 Korea Health Technology R&D Project, aimed at discovering future new growth engines based on innovative research results.
Professor KIM YOUNG JU
The team led by Professor KIM YOUNG JU of the Department of Medicine has been selected for the 2023 Global Research Cooperation Support Project. Consequently, the team will conduct “Korea-UK biohealth joint research for the management of high-risk pregnant women using AI-based multi-omics analysis and organ-on-a-chip analysis” with project funding of KRW 1.25 billion until December 2025. The Global Research Cooperation Support Project was designed to support joint research on healthcare-related fields, such as pharmaceuticals, medical devices, regenerative medicine, digital healthcare and space medicine, conducted in collaboration between Korean researchers and their counterparts from major partner countries including the U.S., Switzerland and the UK. The project is aimed at promoting research cooperation between the researchers involved, effectively secure promising future technologies and enhance Korea’s research competitiveness. This selection will allow the team to conduct multi-ethnic research on the verification of bacterial risk scores and the advancement of bacteria tests for predicting premature births jointly with a research team from the University of Sheffield in the UK, thereby making an early headway into the global market for preterm labor diagnosis and treatment.
Professor Yonghyun Lee, Professor Chang Mo Moon
The team led by Professor Yonghyun Lee of the Department of Pharmacy has been selected for the Human Microbiome-based Diagnosis and Treatment Technology Development Project. The team will conduct research on the “development of inflammatory bowel disease (IBD) treatment technology based on microbiome-control nanobiotics” with project funding of KRW 1.05 billion over the next four years. In a fierce competition with 36 competitors, Professor Lee’s team was selected as the final winner to embark on the development of IBD treatment technology. Professor Lee will conduct joint research with Professor Chang Mo Moon at the Department of Gastroenterology of Ewha Womans University Mokdong Hospital, who is active in carrying out research regarding the treatment of colorectal cancer and IBD, with the aim of discovering new treatment materials through the analysis of IBD-related human microbiome/metabolites and securing nano-bio materials which can modulate the intestinal microbiota community. Ultimately, Professor Lee’s team plans to develop a new, nanobiotics-based treatment technology filled with therapeutic agents and take the lead in developing new microbiome drugs in Korea.
Professor Tae-Jin Song
In addition, the team led by Professor Tae-Jin Song of the Department of Medicine has been selected for a project titled “The Development of Problem-solving Technology in Clinical Care for Brain Nervous System Diseases.” The project was designed to provide support for research topics with significant urgency and ripple effects in the context of problem-solving in the said field, in a bid to satisfy the currently unmet medical needs in the area of cerebral nervous system diseases. Over the next four years, Professor Song’s team will receive a total of KRW 1 billion to develop AI-based digital diagnosis and treatment devices for dysarthria and speech disorders following a stroke. The project will be jointly conducted by Professor Song as well as Professors Moo Seok Park, Yoonkyung Chang, Dong Woo Shin, Min Kyoung Kang and Hyung Woo Lee at the Department of Neurology, and Professors Seo Yon Yang and You Gyoung Yi at the Department of Rehabilitation Medicine at Ewha Womans University Medical Center. Professor Tae-Jin Song was recently selected for a project titled “The Development of Core Original Technology for Human-centered AI” promoted by the Ministry of Science and ICT, thereby demonstrating his lead in researching the development of AI-based digital diagnosis and remedies for nervous system diseases.
Meanwhile, the UroGyn Effectiveness Evaluation Center at Ewha Womans University Mokdong Hospital has been selected as the 2023 Growth-type Disease Effectiveness Evaluation Center, supported by the Ministry of Health and Welfare. The center is set to receive a total of KRW 9 billion over the next five years until 2027 to establish a unique, customized consumer-and-market-oriented system optimized for the evaluation of effectiveness against urinary and female diseases. It will also play a leading role in promoting the development and application of new drugs in Korea by providing advanced and specialized effectiveness evaluation services.